AN

Akash Nagar

Active Director Designated Partner DIN 10006774
DIN 10006774 First appointment Jun 2022 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Akash Nagar

Data last updated:

Akash Nagar is a Designated Partner at Worthcure Pharmaceutical Llp (since 2022). The company operates in Pharma.

DIN 10006774
Primary Designation Designated Partner
Industry Pharma
First Appointment 17 Jun 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner17 Jun 20222022Active

Board colleagues of Akash Nagar

NameDINCompanyDesignation
Komal Patil09163307Worthcure Pharmaceutical LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Worthcure Pharmaceutical Llp
Premium access

Shareholding and investment profile for Akash Nagar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akash Nagar

Akash Nagar currently holds 1 directorship: Worthcure Pharmaceutical Llp (Designated Partner, since 17 Jun 2022).

Akash Nagar was first appointed on 17 Jun 2022 as Designated Partner at Worthcure Pharmaceutical Llp.

The current boards of Akash Nagar's companies include Komal Patil (Worthcure Pharmaceutical Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available